Lusutrombopag and avatrombopag are thrombopoietin receptor agonists used for thrombocytopenia in patients with chronic liver disease and have demonstrated favorable efficacy and safety profiles in clinical trials [6, 7, 8, 9, 10, 11, 12, 13, 14]. The gene discussed is MPL; the disease is Thrombocytopenia.